BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ezhilarasan D. Advantages and challenges in nanomedicines for chronic liver diseases: A hepatologist's perspectives. Eur J Pharmacol 2021;893:173832. [PMID: 33359144 DOI: 10.1016/j.ejphar.2020.173832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Soares GA, Pereira GM, Romualdo GR, Biasotti GGA, Stoppa EG, Bakuzis AF, Baffa O, Barbisan LF, Miranda JRA. Biodistribution Profile of Magnetic Nanoparticles in Cirrhosis-Associated Hepatocarcinogenesis in Rats by AC Biosusceptometry. Pharmaceutics 2022;14:1907. [DOI: 10.3390/pharmaceutics14091907] [Reference Citation Analysis]
2 Ezhilarasan D, Lakshmi T, Mallineni SK. Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges. Nanomedicine. [DOI: 10.2217/nnm-2021-0364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ezhilararasan D, Lakshmi T, Raut B, S VK. Novel Nano-Based Drug Delivery Systems Targeting Hepatic Stellate Cells in the Fibrotic Liver. Journal of Nanomaterials 2021;2021:1-9. [DOI: 10.1155/2021/4674046] [Reference Citation Analysis]
4 Ezhilarasan D. Relaxin in hepatic fibrosis: What is known and where to head? Biochimie 2021;187:144-51. [PMID: 34102254 DOI: 10.1016/j.biochi.2021.06.001] [Reference Citation Analysis]